The FDA's Jan. 31 approval of Amevive (alefacept) for chronic plaque psoriasis represents the first step down an exciting new road, said Alan Menter, M.D, medical director of the Psoriasis Research Center at Baylor University Medical Center.
Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment
New Dermatology Social Comparison Scale Demonstrates Acceptable Psychometrics for Clinical and Research Applications
ReV Up Your Vitiligo Treatment Strategies
A Novel Approach to Distinguishing Scabies From Atopic Dermatitis
Secukinumab Demonstrates Promise for Patients With Severe Hidradenitis Suppurativa Who Found Adalimumab Intolerable